ALK and non-small cell lung carcinoma: Targeted agents against oncogenic driver mutations such as sensitizing mutations in the epidermal growth factor receptor gene (EGFR) and fusions of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), or BRAF V600E have significantly improved the prognosis of advanced NSCLC, with higher response rates and longer progression-free survival than conventional cytotoxic chemotherapy [5,6,7,8,9,10].